1800 244 735

Helpline (02) 9874 9777

Frequently asked questions, January 2011

The first in a monthly series of FAQ articles covering hot topics and burning issues in the science behind HD.

What causes Huntington’s disease?

HD (Huntington’s disease) is caused by a mutation in a person’s DNA. Your DNA is basically lots of instructions for building your body and keeping it running. DNA is organized into individual ‘recipes’ called genes. Each gene is a recipe for one protein (a molecular machine). A mutation in a gene is like a spelling mistake. Some spelling mistakes are harmless, but some result in proteins that don’t work properly or are harmful.

The mutation that causes HD was mapped to a specific gene in 1993 – this gene is now called the ‘huntingtin’ gene, and is abbreviated as ‘HTT’ or ‘HD’ or ‘IT15’. Knowing the location and nature of the HD mutation has allowed people to be tested for the HD mutation since 1993.

So what’s all this about ‘CAG’?

Everyone with HD has the same basic type of mutation. It is an expansion of a normal repetitive piece of DNA on chromosome number 4. Chromosomes are long pieces of DNA which are chains of millions of ‘bases’. Each base is like letters of the alphabet spelling a word. Every base is one of 4 chemicals (adenine, cytosine, guanine, thymine). These bases are abbreviated as A, C, G or T.

Near the beginning of everyone’s HD gene is a repetitive stretch of three letters – CAG. In people without HD, these three bases are repeated fewer than 35 times – usually about 17 times. People with 36 or greater repeats of CAG will develop HD if they live long enough.

Traditionally, CAG is pronounced as three separate letters (‘see-ay-gee’) rather than as a word.

How does an expanded CAG repeat cause Huntington’s disease?

Proteins are made from building blocks called amino acids. The three-base sequence CAG in a gene is an instruction to add an amino acid called glutamine to a growing protein. How ever many CAG repeats there are in a huntingtin gene, is how many glutamines will be in the finished protein. So, for example, people with 42 CAG repeats produce a huntingtin protein with 42 glutamine blocks at the start.

Scientists have abbreviations for the different amino acids. Glutamine is abbreviated as ‘Q’, so Huntingtin’s disease is sometimes called a ‘polyglutamine disease’ or a ‘polyQ disease’.

When the huntingtin protein contains too many glutamine blocks, it has a different shape from the normal protein, and behaves differently too. These differences cause the abnormal protein to become harmful to cells, and it’s this harmful behaviour that causes cells to malfunction and die.

Malfunctioning and dying neurons (brain cells), and other cells, are what causes the symptoms of HD.

Can you tell when someone will experience symptoms of HD?

If we look at thousands of HD patients, we find that on average, people with longer CAG-repeat lengths tend to have an earlier age of onset of HD symptoms. At the extreme, people with very long repeats have a severe form of HD with childhood onset. This is often called ‘juvenile HD’ or ‘jHD’. HD patients with adult onset have CAG repeat counts that are lower than juvenile HD patients. The average repeat length in HD patients is about 44.

It’s important to note that the ability to predict age of onset from CAG-repeat length is not at all accurate. Two people with the same CAG repeat length might start to experience symptoms at very different ages – many years or decades different. Because of this, CAG-repeat lengths are useful for scientific and medical research, but aren’t very informative for most people trying to predict their own expected age of onset.

My friend/brother/mom is taking a particular drug for HD – do you think I should?

HDBuzz can’t provide personal medical advice. Any decisions about treatment of HD symptoms should be pursued in consultation with your physician.

Unfortunately, no treatment or drug has ever been shown to delay or prevent symptoms of HD in humans.

However, there are lots of treatments that can help many of the symptoms of HD, and different people may benefit from different treatments. Ask your HD doctor which treatments, if any, might be helpful for you.

What about supplements? Can you tell me which supplements to use, and how much to take?

No. Lots of people with HD do take supplements like creatine, coenzyme Q and many others, but so far, no supplement has been shown to slow down the disease when tested in a randomized, double-blind placebo-controlled trial (the best kind of scientific trial for answering these questions).

This is not to say that these supplements definitely DON’T work, but merely that they haven’t been proven to do so. Until they have, HDBuzz can’t recommend any supplement or treatment.

A number of sites on the net provide advice about supplement use for those who wish to consider taking them – HDAC.org and HDlighthouse.org, for example.

What about alternative treatments for HD?

There are a number of individuals and organizations marketing ‘alternative’ treatments for HD. Many of these like exercise, massage etc. – may be very helpful to many patients.

Other alternative therapies, often marketed as ‘cures’, include shark cell injections, stem cell injections and dietary supplements. There is no evidence that such treatments are effective for slowing down the progression of HD – and they may actually be harmful. We advise that you speak to a doctor experienced in looking after HD patients before considering any treatment.

Of course, if good scientific evidence is produced that any ‘alternative’ treatments are effective, you’ll hear about it from HDBuzz.

It’s worth considering that an ‘alternative medicine’ which has been proven to work automatically becomes ‘medicine’.

Isn’t it true that drug companies don’t care about HD?

We at HDBuzz believe that drug companies have a critical role to play in developing effective therapies for HD patients. They have the experience and ability to run clinical trials that will prove whether drugs are effective.

In the past, it may have been true that drug companies didn’t dedicate many resources to HD. This has changed, and now many drug companies have HD research programs. HDBuzz endorses no individual company or program, and receives no funding from any pharmaceutical company, but we are pleased that both large pharmaceutical companies and small biotechnology companies now have very serious programs and resources dedicated to HD research.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Published date: 22 October, 2020

While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation to branaplam. An existing drug…for huntingtin lowering? The pharmaceutical company Novartis has announced that the U.S. Food and Drug Administration ... Read more Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Updates from the EHDN Plenary Meeting 2020

Published date: 9 October, 2020

In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar event which comprised presentations on some of the latest scientific research as well as clinical studies of Huntington’s disease (HD). Researchers, doctors, patients and other interested folks, tuned in for an afternoon of talks as well as question and answer sessions to learn ... Read more Updates from the EHDN Plenary Meeting 2020

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Published date: 23 September, 2020

The SIGNAL clinical trial was designed to test a drug called pepinemab in people with early Huntington’s disease. The key results of that trial were recently announced, and unfortunately, pepinemab did not slow or improve HD symptoms as hoped. What was the SIGNAL trial, and who participated? The SIGNAL trial was launched in 2015 by ... Read more Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

When genes are unstable: targeting somatic instability in HD

Published date: 8 September, 2020

What is somatic instability? We tend to think of DNA as a fixed blueprint, an overarching plan for the biological bricks and bridges that constitute our cells, organs, and bodies. But like any good plan, DNA is actually dynamic and adaptable. It gets frequent use as a template for creating the RNA messages that pave ... Read more When genes are unstable: targeting somatic instability in HD

Working as a team: Changes in brain development mean some brain regions may be slacking off

Published date: 17 August, 2020

The effect of the HD genetic expansion on brain development has been a hot topic in HD research. A team of researchers led by Dr. Sandrine Humbert at the Grenoble Institut Neurosciences, examined human fetal tissue to show that the mutant HD gene causes very early changes in the patterns of early brain development. But ... Read more Working as a team: Changes in brain development mean some brain regions may be slacking off

Caution urged for the use of gene-editing technology CRISPR

Published date: 12 August, 2020

A gene-editing tool known as CRISPR has been heralded as a breakthrough technology for scientists in the lab but also as a potential strategy to treat numerous genetic diseases, including Huntington’s. But a series of recent studies has suggested that CRISPR is less precise than previously thought, leading to unintended changes in the genome. Three ... Read more Caution urged for the use of gene-editing technology CRISPR

Welcome to our new website!

Please bear with us while we iron out the last minute wrinkles! If you have any feedback about our new site, please fill out the form below.